ATGC

ATGC is a South Korean biopharmaceutical company dedicated to the development and commercialization of botulinum toxin-based products for medical and aesthetic use. The company's primary focus is on its lead candidates, ATGC-100 and ATGC-110, which are botulinum toxin type A formulations designed for the treatment of glabellar lines and various neurological conditions. ATGC-110 is notably a pure 150kDa toxin complex, engineered to minimize the risk of antibody formation and secondary non-responsiveness in patients. The company leverages advanced manufacturing and purification technologies to produce high-quality biologics in its dedicated GMP facilities. ATGC has established significant distribution and licensing agreements to facilitate the global expansion of its product portfolio.